 "Dr Reddy's Labs ties up with US-based Cutis Pharma for API & drug research")
Dr Reddy’s Laboratories Ltd has entered into API (active pharmaceutical ingredient) supply and joint development agreements with the US-based Cutis Pharma to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
Cutis Pharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, has aggressively invested in its R&D pipeline, recently announcing the opening of a manufacturing centre at its Wilmington, Massachusetts (USA), facility and completion of validation activities supporting its first NDA filing of the company’s lead pipeline drug, RM-01, next year. The partnership with Dr Reddy’s Laboratories will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval.
“This partnership has significant strategic benefits for both parties. Dr Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards new drug application (NDA) filings,” commented Neal Muni, chief executive officer of Cutis Pharma.
Deepak Sapra, vice president & global head, CPS business of Dr Reddy’s Laboratories, said, “We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with Cutis Pharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”
Muni added, “By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the US as well as select international markets.”
Cutis Pharma Inc is a privately held, specialty pharmaceutical company focusing on the development and commercialisation of value-added proprietary pharmaceutical products and technologies in the prescription compounding sector of the health care industry. The product line and development efforts are focused on providing optimised, more efficient alternatives for the preparation of compounded prescriptions, by offering FIRST unit-of-use prescription compounding kits. Use of these branded compounding kits benefits all key stakeholders, including physicians, pharmacists and patients.
Cutis Pharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, has aggressively invested in its R&D pipeline, recently announcing the opening of a manufacturing centre at its Wilmington, Massachusetts (USA), facility and completion of validation activities supporting its first NDA filing of the company’s lead pipeline drug, RM-01, next year. The partnership with Dr Reddy’s Laboratories will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval.
“This partnership has significant strategic benefits for both parties. Dr Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards new drug application (NDA) filings,” commented Neal Muni, chief executive officer of Cutis Pharma.
Deepak Sapra, vice president & global head, CPS business of Dr Reddy’s Laboratories, said, “We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with Cutis Pharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”
Muni added, “By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the US as well as select international markets.”
Cutis Pharma Inc is a privately held, specialty pharmaceutical company focusing on the development and commercialisation of value-added proprietary pharmaceutical products and technologies in the prescription compounding sector of the health care industry. The product line and development efforts are focused on providing optimised, more efficient alternatives for the preparation of compounded prescriptions, by offering FIRST unit-of-use prescription compounding kits. Use of these branded compounding kits benefits all key stakeholders, including physicians, pharmacists and patients.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%